Untangling methods to tamper with opioid formulations: Perspectives from the benchtop to the real world

Featured speakers include:
Christopher Altomare, B.S. Director, Pharmaceutical Services
Greg Gironda, VP Business Development

Topics covered: This webinar features interviews with recreational and dependent prescription opioid abusers offering a rare look into the manipulation techniques abusers use to prepare opioid tablets for routes of administration that provide a more powerful euphoria, such as intravenous or intranasal. The webinar also discusses the laboratory experiments DRUGSCAN scientists conduct to evaluate the properties of abuse-deterrent formulations that are designed to resist these manipulation techniques


DRUGSCAN CAT.one In Vitro Mastication Studies for Abuse-Deterrent Formulations

Featured speakers include:
Eric Kinzler, PhD, Study Director
Christopher Altomare, B.S. Director, Pharmaceutical Services

Topics covered: Eric Kinzler and Chris Altomare of DRUGSCAN discuss designing in vitro mastication studies for abuse-deterrent formulations.


Webinar on Best Practices and the FDA’s Abuse-Deterrent Guidance for Innovator and Generic Opioids

Featured speakers include:
Daniel Leach, B.Sc (Hons), Director of Pharmaceutical Services DRUGSCAN, Inc.
Edward Cone, Ph.D., Principal Scientist, Drug Delivery and Abuse-Deterrent Drug Products, PinneyAssociates.
Beatrice Setnik, Ph.D., Vice President of Clinical Pharmacology Early Phase, INC Research.

Topics covered: Describe the similarities and differences between the FDA’s innovator and generic guidance for abuse-deterrent opioids and their target audiences
Review best practices for conducting studies to evaluate abuse resistance and abuse potential.